Mefenamic Acid and Methotrexate Interaction

Understanding the Mefenamic Acid and Methotrexate Interaction

FDA-approved prescribing information for these two drugs flags their combination as a moderate-severity interaction. Mefenamic Acid belongs to the Nonsteroidal Anti-Inflammatory Drug (NSAID) class and Methotrexate belongs to the Disease-Modifying Antirheumatic Drug (DMARD) class - two categories that can collide when co-prescribed. The mechanism described in FDA labeling is: This pain medicine can prevent your body from clearing out methotrexate, which can lead to toxic levels in your system. Severity tiers matter: major flags generally advise avoidance, moderate flags often require monitoring or dose adjustment, and minor flags may only call for awareness.

Context around a specific patient determines real-world impact. Mefenamic Acid has 15 total documented interactions on file in this dataset, and Methotrexate has 38. Each additional medication compounds the interaction surface, which is why pharmacists run full-profile checks rather than evaluating one pair at a time. FDA-derived guidance for this pair is: Your doctor should monitor you for signs of toxicity, such as kidney issues or changes in your blood cell counts. Timing of doses, renal and hepatic function, age, and other concurrent prescriptions all shape whether a labeled interaction matters clinically.

An interaction flag is not a verdict. A large share of labeled interactions are managed routinely in clinical practice, the fix may be as simple as spacing doses or adding a monitoring test. Others require the prescriber to choose a different medication entirely. This page surfaces FDA-sourced labeling and openFDA data for educational purposes only; it is not medical advice and cannot account for your full clinical picture. Never start, stop, or adjust either Mefenamic Acid or Methotrexate based on a web page, speak with your prescriber or pharmacist before making any change.